| Cause of sudden, unexpected death of Prader-Willi syndrome patients with or without growth hormone treatment. | |
| | |
MedLine Citation:
|
PMID: 15937939 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients with Prader-Willi syndrome (PWS) are recognized to have a tendency of sudden, unexpected death (SED), but its exact cause is unknown because of paucity of such case reports. Since growth hormone (GH) treatment was applied to PWS patients worldwide, several cases of death have been reported. However, whether the therapy is directly related to their SED remains unknown, too. We collected 13 deceased PWS patients (Group A, aged 9 months to 34 years) who had never received GH therapy, and seven deceased patients (Group B, all boys aged 0.7-15 years) having received the therapy from the registration in PWS-patient-support associations and from the literature, respectively. We then compared the cause of SED between the two groups. Irrespective of GH therapy, SED of infants under age 1 year was associated with milk aspiration or hypothalamic dysregulation of respiration, while SED of patients in early childhood or adolescence occurred at sleeping in association with preceding viral infections. In contrast, SED of four adult (>20 years of age) patients who never received GH therapy was associated with complications, such as leg cellulites and pulmonary embolism, secondary to massive obesity and diabetes mellitus (DM). Two Group-B patients (aged 14 and 20 years) without any obesity-related or diabetes-related complications died of drowning in a bath tub, and their drowning death could be related to poor respiratory control. These findings indicated that the cause of SED is not essentially different between PWS patients with and without GH treatment. Deceased PWS patients may have had underlying respiratory dysregulation and hypothalamic dysfunction, and GH therapy might have led to certain obstructive respiratory disturbances that exacerbated the respiratory conditions. This will call clinicians' attention when using GH in PWS patients, for example, careful determination of the dose of GH and careful monitoring of patient's respiratory conditions, especially in male obese patients with respiratory problems. |
| | |
Authors:
|
T Nagai; K Obata; H Tonoki; S Temma; N Murakami; Y Katada; A Yoshino; S Sakazume; E Takahashi; R Sakuta; N Niikawa |
Related Documents
:
|
20627449 - Cortisol levels and adrenal response in severe community-acquired pneumonia: a systemat... 2322519 - Ptosis as the early manifestation of pituitary tumour. 8306479 - Adrenocorticotrophin stimulation and hla polymorphisms suggest a high frequency of hete... 1759539 - Chronic treatment with parlodel lar of patients with prolactin-secreting tumours. diffe... 10353939 - Growth, puberty, and endocrine functions in patients with sporadic or familial neurofib... 2550959 - Patterns of endocrine secretion during sepsis. 22285399 - Risk factors for non-calcified plaques in asymptomatic population. 588129 - The value of sialography in the diagnosis of parotid tumors. a clinicopathological corr... 3763509 - Carotid endarterectomy. controversies and recommendations. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: American journal of medical genetics. Part A Volume: 136 ISSN: 1552-4825 ISO Abbreviation: Am. J. Med. Genet. A Publication Date: 2005 Jul |
Date Detail:
|
Created Date: 2005-06-29 Completed Date: 2005-08-10 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101235741 Medline TA: Am J Med Genet A Country: United States |
Other Details:
|
Languages: eng Pagination: 45-8 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2005 Wiley-Liss, Inc. |
Affiliation:
|
Department of Pediatrics, Dokkyo University School of Medicine Koshigaya Hospital, Saitama, Japan. t-nagai@dokkyomed.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Age Factors Cause of Death Child Child, Preschool Death, Sudden / etiology* Diarrhea / complications Female Growth Hormone / therapeutic use* Humans Infant Male Prader-Willi Syndrome / complications*, drug therapy, mortality Pulmonary Embolism / complications Virus Diseases / complications |
| Chemical | |
Reg. No./Substance:
|
9002-72-6/Growth Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Runx3 is involved in hair shape determination.
Next Document: Identification of an alternative 5'-untranslated exon and new polymorphisms of angiotensin-convertin...